CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net income	$ 59,229	$ 220,541
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income tax	5,984	45,069
Depreciation and amortization	7,092	6,918
Stock-based compensation	2,304	921
Amortization of debt discount and issuance costs	931	4,472
Changes in fair values of equity and long-term investments, net	68,011	(99,046)
Loss on extinguishment of debt	20,662	0
Other	857	16
Changes in operating assets and liabilities:
Receivables from collaborative arrangements	(965)	(10,331)
Prepaid expenses	2,968	578
Other assets, current	910	328
Other assets, non-current	(844)	0
Accounts payable	2,713	(36)
Accrued personnel-related expenses and other accrued liabilities	6,939	(709)
Accrued interest payable	346	0
Net cash provided by operating activities	177,137	168,721
Cash flows from investing activities
Purchases of equity and long term investments	(58,726)	(46,373)
Purchases of equity investments managed by ISP Fund LP	(38,026)	(142,636)
Sale of equity investments managed by ISP Fund LP	24,281	18,545
Purchase and sales of other investments managed by ISP Fund LP, net	(96,255)	234,091
Purchases of property and equipment	(22)	0
Cash acquired through the consolidation of Entasis Therapeutics Holdings, Inc.	23,070	0
Net cash provided by (used in) investing activities	(145,678)	63,627
Cash flows from financing activities
Distributions to noncontrolling interest	(16,054)	(41,446)
Repurchase of common stock	0	(394,149)
Repurchase of shares to satisfy tax withholding	(59)	(35)
Proceeds from issuances of common stock, net	341	60
Payment for repurchase of convertible subordinated notes due 2023	(165,131)	0
Purchases of capped call options associated with convertible senior notes due 2028	(21,037)	0
Proceeds from issuance of convertible senior notes due 2028, net of issuance costs	252,536	0
Net cash provided by (used in) financing activities	50,596	(435,570)
Net increase (decrease) in cash and cash equivalents	82,055	(203,222)
Cash and cash equivalents at beginning of period	201,525	246,487
Cash and cash equivalents at end of period	283,580	43,265
Supplemental disclosure of cash flow information
Cash paid for interest	5,411	4,967
Supplemental disclosure of non-cash investing and financing activities
Right-of-use asset obtained through the consolidation of Entasis Therapeutics Holdings, Inc.	3,289	0
ASU 2020-06
Supplemental disclosure of non-cash investing and financing activities
Adoption of ASU 2020-06	$ 28,123	$ 0